Quantitative Investment Management LLC Makes New Investment in Hims & Hers Health, Inc. $HIMS

Key Points

• Quantitative Investment Management LLC initiated a new stake of 181,633 shares in Hims & Hers (~$10.3M), representing about 0.08% of the company and roughly 1.4% of the firm's portfolio (its 16th largest holding); institutional investors now own ~63.5% of HIMS.
• Hims & Hers beat EPS estimates ($0.08 vs. $0.02) with revenue up 28.4% YoY and the board authorized a $250M share buyback, while a strategic alliance with Novo Nordisk has reduced legal overhang and spurred some analyst upgrades — yet consensus remains a "Hold" and regulatory/legal risks persist.

Quantitative Investment Management LLC acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 181,633 shares of the company's stock, valued at approximately $10,302,000. Hims & Hers Health accounts for about 1.4% of Quantitative Investment Management LLC's investment portfolio, making the stock its 16th biggest holding. Quantitative Investment Management LLC owned approximately 0.08% of Hims & Hers Health at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Virtus Advisers LLC purchased a new position in shares of Hims & Hers Health in the second quarter worth $26,000. Quent Capital LLC purchased a new stake in Hims & Hers Health during the 3rd quarter valued at $28,000. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health during the 1st quarter valued at $30,000. Hilltop National Bank bought a new stake in Hims & Hers Health in the 3rd quarter worth $35,000. Finally, Skandinaviska Enskilda Banken AB publ grew its holdings in Hims & Hers Health by 408.2% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock worth $37,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on HIMS shares. BTIG Research downgraded shares of Hims & Hers Health from a "buy" rating to a "neutral" rating in a research note on Tuesday, February 24th. Zacks Research raised Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $25.00 to $28.00 and gave the company a "hold" rating in a report on Tuesday. Barclays increased their price objective on Hims & Hers Health from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, Evercore set a $24.00 price objective on Hims & Hers Health in a research report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Hims & Hers Health currently has an average rating of "Hold" and an average price target of $30.75.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $23.88 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The stock's 50 day simple moving average is $24.01 and its two-hundred day simple moving average is $37.57. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The stock has a market cap of $5.44 billion, a price-to-earnings ratio of 46.81, a PEG ratio of 2.45 and a beta of 2.55.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business's revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.11 EPS. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has authorized a share buyback program on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's board believes its shares are undervalued.

Insider Buying and Selling

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares in the company, valued at approximately $6,238,497.40. This represents a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Chi sold 13,750 shares of the business's stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer owned 305,161 shares in the company, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 80,463 shares of company stock valued at $2,846,696 over the last 90 days. 13.71% of the stock is currently owned by company insiders.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Large strategic win — the Novo Nordisk alliance replaces risky compounded GLP‑1 sales with branded Wegovy/Ozempic distribution, materially reducing legal exposure and opening recurring revenue from branded weight‑loss drugs; this is a key reason for intraday rallies. Hims & Hers Stock Jumps After Novo Deal
• Positive Sentiment: Wall Street is turning more constructive: Barclays raised its price target to $29 (overweight) and other shops (Needham, Deutsche Bank coverage) have upgraded or issued favorable notes — these ratings helped fuel buyer interest and reduce some uncertainty. Barclays Raises HIMS Target to $29
• Positive Sentiment: Management hires to support the growth phase — Hims & Hers named Kathryn Beiser as Chief Communications Officer to lead external messaging as the company pursues domestic and international expansion, which can help brand & regulatory narrative management. CCO Appointment
• Neutral Sentiment: Speculative activity and intraday momentum — unusually large call option buying and big premarket jumps (reported 7% premarket) indicate elevated investor interest and short‑term positioning; this raises volatility but is not a fundamentals guarantee. Options & Volume Spike
• Negative Sentiment: Regulatory and legal risks remain meaningful — prior FDA scrutiny of compounded GLP‑1s, a Novo Nordisk patent lawsuit and potential DOJ attention continue to weigh on margin visibility and could limit near‑term upside if unresolved. Regulatory & Legal Overhang
• Negative Sentiment: Short-term price pressure and recent drawdown — coverage pieces note a ~29% three‑month decline and intraday moves where HIMS fell more than the broader market; that reflects profit‑taking, headline risk and rotation away from higher‑beta names. Why HIMS Fell More Than Market

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.